Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | EYA2 | O00167 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29223009 | 0.95 | BLM (0.61) | BLMLMNATDP1TSHRPMP22 | |
| SCHEMBL12583942 | 0.95 | BLM (0.54) | BLMLMNATDP1TSHRPMP22 | |
| SCHEMBL1420542 | 0.95 | TDP1 (0.62) | BLMLMNATDP1TSHRPMP22 | |
| SCHEMBL31040438 | 0.93 | BLM (0.52) | BLMLMNATDP1TSHRPMP22 | |
| SCHEMBL4955509 | 0.93 | BLM (0.56) | BLMLMNATDP1TSHRPMP22 | |
| SCHEMBL27720097 | 0.93 | TDP1 (0.59) | BLMLMNATDP1TSHRPMP22 | |
| Hydrochloric Acid SCHEMBL26104340 | 0.91 | BLM (0.50) | BLMLMNATDP1TSHRPMP22 | |
| SCHEMBL15831761 | 0.87 | BLM (0.62) | BLMLMNATDP1TSHRPMP22 | |
| SCHEMBL432612 | 0.86 | CA12 (0.46) | BLMLMNATDP1TSHRPMP22 | |
| SCHEMBL2808370 | 0.86 | TDP1 (0.56) | BLMLMNATDP1TSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595496-B1 | ANTIMICROBIAL PEPTIDE, BRANCHED FORMS THEREOF AND THEIR USE IN THE TREATMENT OF BACTERIA INFECTIONS | SETLANCE S R L (IT) | 2014-06-04 | — | — | EP | claimed |
| US-20140112976-A1 | Cyclic Peptides with an Anti-Neoplasic and Anti-Angiogenic Activity | CENTRO DE INGENIERIA GENETICA BIOTECNOLOGIA (CU) | 2014-04-24 | — | — | US | claimed |
| EP-2690107-A2 | CYCLIC PEPTIDES WITH AN ANTI-NEOPLASIC AND ANTI-ANGIOGENIC ACTIVITY | Centro De Ingenieria Genetica Y Biotecnologia (CU) | 2014-01-29 | — | — | EP | claimed |
| EP-2595496-A1 | ANTIMICROBIAL PEPTIDE, BRANCHED FORMS THEREOF AND THEIR USE IN THE TREATMENT OF BACTERIA INFECTIONS | Setlance S.r.L. (IT) | 2013-05-29 | — | — | EP | claimed |
| US-20130130969-A1 | ANTIMICROBIAL PEPTIDE, BRANCHED FORMS THEREOF AND THEIR USE IN THE TREATMENT OF BACTERIA INFECTIONS | SETLANCE S.R.L. (IT) | 2013-05-23 | — | — | US | claimed |
| WO-2012010266-A1 | ANTIMICROBIAL PEPTIDE, BRANCHED FORMS THEREOF AND THEIR USE IN THE TREATMENT OF BACTERIA INFECTIONS | SETLANCE S.R.L. (IT) | 2012-01-26 | — | — | WO | claimed |
| EP-2409579-A1 | Antimicrobial peptide, branched forms and uses thereof for the cure of bacteria infections | Setlance S.r.L. (IT) | 2012-01-25 | — | — | EP | claimed |
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | claimed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250325644-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | ELICIO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20040242842-A1 | Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use | UNIVERSITY OF BERN (CH) | 2004-12-02 | — | — | US | disclosed |
| WO-2004101739-A2 | METHODS FOR CHEMICALLY SYNTHESIZING IMMUNOGLOBULIN CHIMERIC PROTEINS | SYNTONIX PHARMACEUTICALS, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1283216-A1 | Somatostatin analogues binding to all somatostatin receptor subtypes and their use | Mallinckrodt Inc. (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6388054-B1 | AMINO ACID SEQUENCES OF ANTITUMOR AGENTS AND APOPTOSIS AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-14 | — | — | US | disclosed |
| US-5935932-A | Bradykinin antagonists containing pentafluorophenylalanine | UNIVERSITY TECHNOLOGY CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| US-4728542-A | POLYURETHANES; WATER VAPOR PERMEABLE COATINGS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | BLM 3907/4885LMNA 2888/4885TDP1 3694/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | BLM 3409/4885LMNA 1747/4885TDP1 3646/4885 |
| US-20130130969-A1 | ANTIMICROBIAL PEPTIDE, BRANCHED FORMS THEREOF AND THEIR USE IN THE TREATMENT OF BACTERIA INFECTIONS | VIP, PEPD, DNPEP | BLM 3569/4885LMNA 3218/4885TDP1 4117/4885 |
| US-20040242842-A1 | Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use | SSTR5, NPY5R, GLP1R | BLM 3021/4885LMNA 792/4885TDP1 3168/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | BLM 1447/4885LMNA 2073/4885TDP1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.